{
     "PMID": "29378212",
     "OWN": "NLM",
     "STAT": "Publisher",
     "LR": "20180302",
     "IS": "1873-7064 (Electronic) 0028-3908 (Linking)",
     "VI": "133",
     "DP": "2018 Jan 31",
     "TI": "Systemic blockade of LPA1/3 lysophosphatidic acid receptors by ki16425 modulates the effects of ethanol on the brain and behavior.",
     "PG": "189-201",
     "LID": "S0028-3908(18)30033-9 [pii] 10.1016/j.neuropharm.2018.01.033 [doi]",
     "AB": "The systemic administration of lysophosphatidic acid (LPA) LPA1/3 receptor antagonists is a promising clinical tool for cancer, sclerosis and fibrosis-related diseases. Since LPA1 receptor-null mice engage in increased ethanol consumption, we evaluated the effects of systemic administration of an LPA1/3 receptor antagonist (intraperitoneal ki16425, 20mg/kg) on ethanol-related behaviors as well as on brain and plasma correlates. Acute administration of ki16425 reduced motivation for ethanol but not for saccharine in ethanol self-administering Wistar rats. Mouse experiments were conducted in two different strains. In Swiss mice, ki16425 treatment reduced both ethanol-induced sedation (loss of righting reflex, LORR) and ethanol reward (escalation in ethanol consumption and ethanol-induced conditioned place preference, CPP). Furthermore, in the CPP-trained Swiss mice, ki16425 prevented the effects of ethanol on basal c-Fos expression in the medial prefrontal cortex and on adult neurogenesis in the hippocampus. In the c57BL6/J mouse strain, however, no effects of ki16425 on LORR or voluntary drinking were observed. The c57BL6/J mouse strain was then evaluated for ethanol withdrawal symptoms, which were attenuated when ethanol was preceded by ki16425 administration. In these animals, ki16425 modulated the expression of glutamate-related genes in brain limbic regions after ethanol exposure; and peripheral LPA signaling was dysregulated by either ki16425 or ethanol. Overall, these results suggest that LPA1/3 receptor antagonists might be a potential new class of drugs that are suitable for treating or preventing alcohol use disorders. A pharmacokinetic study revealed that systemic ki16425 showed poor brain penetration, suggesting the involvement of peripheral events to explain its effects.",
     "CI": [
          "Copyright (c) 2018 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Sanchez-Marin, Laura",
          "Ladron de Guevara-Miranda, David",
          "Manas-Padilla, M Carmen",
          "Alen, Francisco",
          "Moreno-Fernandez, Roman D",
          "Diaz-Navarro, Caridad",
          "Perez-Del Palacio, Jose",
          "Garcia-Fernandez, Maria",
          "Pedraza, Carmen",
          "Pavon, Francisco J",
          "Rodriguez de Fonseca, Fernando",
          "Santin, Luis J",
          "Serrano, Antonia",
          "Castilla-Ortega, Estela"
     ],
     "AU": [
          "Sanchez-Marin L",
          "Ladron de Guevara-Miranda D",
          "Manas-Padilla MC",
          "Alen F",
          "Moreno-Fernandez RD",
          "Diaz-Navarro C",
          "Perez-Del Palacio J",
          "Garcia-Fernandez M",
          "Pedraza C",
          "Pavon FJ",
          "Rodriguez de Fonseca F",
          "Santin LJ",
          "Serrano A",
          "Castilla-Ortega E"
     ],
     "AD": "Unidad de Gestion Clinica de Salud Mental, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Regional Universitario de Malaga, Spain. Departamento de Psicobiologia y Metodologia de las Ciencias del Comportamiento, Instituto de Investigacion Biomedica de Malaga (IBIMA), Facultad de Psicologia, Universidad de Malaga, Spain. Centro de Experimentacion Animal, Instituto de Investigacion Biomedica de Malaga (IBIMA), Facultad de Medicina, Universidad de Malaga, Spain. Unidad de Gestion Clinica de Salud Mental, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Regional Universitario de Malaga, Spain. Departamento de Psicobiologia y Metodologia de las Ciencias del Comportamiento, Instituto de Investigacion Biomedica de Malaga (IBIMA), Facultad de Psicologia, Universidad de Malaga, Spain. Fundacion MEDINA, Parque Tecnologico Ciencias de la Salud, Avenida del Conocimiento 34, 18016, Granada, Spain. Fundacion MEDINA, Parque Tecnologico Ciencias de la Salud, Avenida del Conocimiento 34, 18016, Granada, Spain. Departamento de Fisiologia Humana, Instituto de Investigacion Biomedica de Malaga (IBIMA), Facultad de Medicina, Universidad de Malaga, Spain. Departamento de Psicobiologia y Metodologia de las Ciencias del Comportamiento, Instituto de Investigacion Biomedica de Malaga (IBIMA), Facultad de Psicologia, Universidad de Malaga, Spain. Unidad de Gestion Clinica de Salud Mental, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Regional Universitario de Malaga, Spain. Unidad de Gestion Clinica de Salud Mental, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Regional Universitario de Malaga, Spain. Departamento de Psicobiologia y Metodologia de las Ciencias del Comportamiento, Instituto de Investigacion Biomedica de Malaga (IBIMA), Facultad de Psicologia, Universidad de Malaga, Spain. Electronic address: luis@uma.es. Unidad de Gestion Clinica de Salud Mental, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Regional Universitario de Malaga, Spain. Electronic address: antonia.serrano@ibima.eu. Unidad de Gestion Clinica de Salud Mental, Instituto de Investigacion Biomedica de Malaga (IBIMA), Hospital Regional Universitario de Malaga, Spain. Electronic address: estela.castilla@ibima.eu.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20180131",
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Alcohol",
          "Autotaxin",
          "Conditioned place preference",
          "Self-administration",
          "Two-bottle choice",
          "Withdrawal"
     ],
     "EDAT": "2018/01/30 06:00",
     "MHDA": "2018/01/30 06:00",
     "CRDT": [
          "2018/01/30 06:00"
     ],
     "PHST": [
          "2017/11/23 00:00 [received]",
          "2018/01/24 00:00 [accepted]",
          "2018/01/30 06:00 [pubmed]",
          "2018/01/30 06:00 [medline]",
          "2018/01/30 06:00 [entrez]"
     ],
     "AID": [
          "S0028-3908(18)30033-9 [pii]",
          "10.1016/j.neuropharm.2018.01.033 [doi]"
     ],
     "PST": "aheadofprint",
     "SO": "Neuropharmacology. 2018 Jan 31;133:189-201. doi: 10.1016/j.neuropharm.2018.01.033.",
     "term": "hippocampus"
}